Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

THE ABSORB III RANDOMIZED CONTROLLED TRIAL (RCT)

Study:

A Clinical Evaluation of Absorbâ„¢ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.

Rationale:

n/a

Purpose:

A Clinical Evaluation of Absorbâ„¢ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Disease
Coronary Stenosis
Device: Absorb BVS
Device: XIENCE V or XIENCE PRIME
N/A

Verified by Abbott Vascular November, 2013

Sponsored by: Abbott Vascular
Information provided by: Abbott Vascular
ClinicalTrials.gov identifier: NCT01751906

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Stephen G Ellis, MD., Principal Investigator
Dean J Kereiakes, MD., Principal Investigator
Gregg W Stone, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site